Goldcrest Capital

Activity in this selectiongoldman-sachs-alternatives-life-sciences-c1335a4c

By stage

Series A2

Series C+1

Enterprise software2

Biotech1

United States3

3 in this selection

Aug 11

Develops human-derived antibody therapeutics for atopic dermatitis and inflammatory disease

$75MSeries A

Role not disclosed

Jun 23

Builds AI platform for operational clarity in government and public safety

$250MSeries D

Role not disclosed

Jan 29

Develops mission-specific AI applications on the Palantir operating system

$22MSeries A

Role not disclosed